Real-world effects of anti-vascular endothelial growth factor injection frequency on visual outcomes in patients with diabetic macular oedema
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Real-world effects of anti-vascular endothelial growth factor injection frequency on visual outcomes in patients with diabetic macular oedema ; day:6 ; month:3 ; year:2024 ; pages:1-7
Eye ; (6.3.2024), 1-7
- Creator
-
Payne, Carter J.
Gupta, Urvi
Maatouk, Christopher M.
Kuo, Blanche L.
Perkins, Scott W.
Singh, Rishi P.
Talcott, Katherine E.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41433-024-02998-2
- URN
-
urn:nbn:de:101:1-2405100915002.013287096208
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Payne, Carter J.
- Gupta, Urvi
- Maatouk, Christopher M.
- Kuo, Blanche L.
- Perkins, Scott W.
- Singh, Rishi P.
- Talcott, Katherine E.
- SpringerLink (Online service)
Other Objects (12)
Minimally invasive laser treatment combined with intravitreal injection of anti-vascular endothelial growth factor for diabetic macular oedema
How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient outcomes in diabetic macular oedema
Anti-vascular endothelial growth factor dosing frequency and visual outcomes in macular oedema following branch retinal vein occlusion
Suboptimal outcomes and treatment burden of anti-vascular endothelial growth factor treatment for diabetic macular oedema in phakic patients
Influence of macular oedema on the measurement of macular pigment optical density
Association between the response of intravitreal antivascular endothelial growth factor injection and systemic factors of diabetic macular edema
CMV retinitis and subsequent acute cystoid macular oedema after treatment with vitreous ganciclovir injection: a case report
Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland
Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion
Real-world outcomes of intravitreal bevacizumab treat-and-extend for cystoid macular oedema secondary to central retinal vein occlusion
Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema
Cystoid macular oedema associated with Rosai–Dorfman disease: a case report
Minimally invasive laser treatment combined with intravitreal injection of anti-vascular endothelial growth factor for diabetic macular oedema
How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient outcomes in diabetic macular oedema
Anti-vascular endothelial growth factor dosing frequency and visual outcomes in macular oedema following branch retinal vein occlusion
Suboptimal outcomes and treatment burden of anti-vascular endothelial growth factor treatment for diabetic macular oedema in phakic patients
Influence of macular oedema on the measurement of macular pigment optical density
Association between the response of intravitreal antivascular endothelial growth factor injection and systemic factors of diabetic macular edema
CMV retinitis and subsequent acute cystoid macular oedema after treatment with vitreous ganciclovir injection: a case report
Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland
Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion
Real-world outcomes of intravitreal bevacizumab treat-and-extend for cystoid macular oedema secondary to central retinal vein occlusion
Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema
Cystoid macular oedema associated with Rosai–Dorfman disease: a case report
Minimally invasive laser treatment combined with intravitreal injection of anti-vascular endothelial growth factor for diabetic macular oedema
How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient outcomes in diabetic macular oedema
Anti-vascular endothelial growth factor dosing frequency and visual outcomes in macular oedema following branch retinal vein occlusion
Suboptimal outcomes and treatment burden of anti-vascular endothelial growth factor treatment for diabetic macular oedema in phakic patients
Influence of macular oedema on the measurement of macular pigment optical density
Association between the response of intravitreal antivascular endothelial growth factor injection and systemic factors of diabetic macular edema
CMV retinitis and subsequent acute cystoid macular oedema after treatment with vitreous ganciclovir injection: a case report
Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland
Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion
Real-world outcomes of intravitreal bevacizumab treat-and-extend for cystoid macular oedema secondary to central retinal vein occlusion
Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema